$ cat ./records/gates-foundation-backs-path-typhoid-conjugate-vaccine-trials-in-n-2013.txt
Gates Foundation Backs PATH Typhoid Conjugate Vaccine Trials in Nepal and Pakistan
[RECORD.TXT] · cat --full
The Gates Foundation funded PATH to conduct a large randomised controlled trial of typhoid conjugate vaccine (TCV) efficacy, enrolling children in Nepal and Pakistan. The Nepal trial showed 81 percent efficacy and was submitted to WHO for prequalification of Bharat Biotech's Typbar-TCV — the world's first TCV approved by a stringent regulatory authority. Typhoid kills 128,000 people annually, predominantly children in South Asia and Sub-Saharan Africa where sanitation infrastructure is limited.
Source: https://www.path.org/our-impact/case-studies/typhoid-conjugate-vaccines/
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Funds PATH RSV Maternal Vaccine Program to Protect Newborns in Developing Countries
Next →
Gates Invests in Beyond Meat — Plant-Based Meat Reducing Land and Water Use
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.